SCHEDULE: Adage Capital Boosts Praxis Medicines Stake to 9.69%
Beneficial Ownership Report
Adage Capital Management, L.P. and its principals have reported a 9.69% beneficial ownership stake in Praxis Precision Medicines, Inc.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 1,974,585 shares of Praxis Precision Medicines, Inc. Common Stock.
- This represents 9.69% of the company's outstanding Common Stock.
- The percentage is calculated based on 20,368,982 shares outstanding as of April 30, 2025, as reported in the company's Form 10-Q filed on May 2, 2025.
- The reporting persons hold shared voting and dispositive power over all 1,974,585 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor. The significant stake by Adage Capital Management could be interpreted as a positive signal of confidence in the company, though the filing itself is purely factual and does not contain performance data.
Positives
- A significant institutional investor, Adage Capital Management, L.P., holds a substantial 9.69% stake, which can be interpreted as a signal of confidence in Praxis Precision Medicines, Inc.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an institutional investor and does not provide specific industry context or analysis.
Stakeholder Impact
- Shareholders: Increased institutional ownership may provide stability and signal confidence, potentially attracting other investors.
Key Dates
| Date | Description |
|---|---|
| 2025-04-30 | Date as of which 20,368,982 shares of Common Stock were reported outstanding in the Company's Form 10-Q. |
| 2025-05-02 | Date the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025, was filed with the SEC. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-12 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Praxis Precision Medicines, Adage Capital Management, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.